Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- Govt to Hear Opinions from Trade, Professional Groups on Generic Promotion
May 12, 2015
- Applications for Sakigake Review System May Be Accepted from Early Stage of Development: Official
May 12, 2015
- Editor’s Pick: Five Healthcare News Headlines for April 20 - May 10
May 11, 2015
- PMDA Evaluating Xalkori for Risk of Cardiac Failure
May 11, 2015
- Chuikyo to Discuss Listing of Gilead’s Sovaldi on May 13; Listing Could Take Place This Month
May 11, 2015
- 10-Year Reexamination Period Possible for Repositioned Drugs under Sakigake System: Official
May 8, 2015
- DPC Hospitals with Generic Use Rates Above 60% More Than Doubled
May 1, 2015
- MHLW to Give Medical Subsidies for 196 “Designated Intractable Diseases” from July
May 1, 2015
- PAFSC 1st Committee Recommends Irribow Use in Females
May 1, 2015
- Submission of CDISC-Based Clinical Data Required from October 2016: Notification
April 30, 2015
- Thrombocytopenia Added to Clinically Significant ADR List for Januvia, Glactiv: Safety Bulletin
April 30, 2015
- Scrutinize Purpose of Price Maintenance Premium for New Drugs: MOF
April 28, 2015
- MOF Presses for 80% Generic Share Target by FY2017
April 28, 2015
- Number of Topics Discussed by PAFSC Second Committee Exceeds that of First Committee for 1st Time in 10 Years: Jiho Tally
April 28, 2015
- Patient-Initiated Mixed Care Used Only When Compassionate Access Can’t Be Applied: Minister
April 28, 2015
- PAFSC Second Committee Backs Approval of Add’l Indication for PegIntron
April 27, 2015
- AMED, JPMA Discussing Joint Use of Compounds, with Policy Announcement Expected in Early June: Dr Suematsu of AMED
April 27, 2015
- MHLW Looking into Drug Maker Payments to PAFSC Members: Shiozaki
April 24, 2015
- LDP Weighs Clinical Development Infrastructure Utilizing Patient Registry
April 24, 2015
- Council on Unapproved Drugs to Issue Development Requests Immediately In Cases of Unanimous Approval by Working Groups
April 24, 2015
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…